Evidence map›Paper›PMID 35290591›Full record

ReviewTargeted oncology2022

The Management of Unresectable, Advanced Gastrointestinal Stromal Tumours.

Tiffany Foo, David Goldstein, Eva Segelov, Jeremy Shapiro, Nick Pavlakis, Jayesh Desai, Desmond Yip, John Zalcberg, Timothy J Price, Adnan Nagrial and 5 more

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Targeted oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.8field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 12 institutions in 1 country.

Tiffany FooFlinders Centre for Innovation in Cancer/Flinders University, Bedford Park, SA, 5042, Australia.
David GoldsteinDepartment of Medical Oncology, Prince of Wales Hospital, University of NSW, Sydney, NSW, Australia.
Eva SegelovDepartment of Medical Oncology, School of Clinical Sciences, Monash University and Monash Health, Melbourne, VIC, Australia.
Jeremy ShapiroCabrini Health, Monash University, Melbourne, VIC, Australia.
Nick PavlakisDepartment of Medical Oncology, Royal North Shore Hospital, University of Sydney, Sydney, NSW, Australia.
Jayesh DesaiPeter MacCallum Cancer Centre, Melbourne, VIC, Australia.
Desmond YipDepartment of Medical Oncology, Canberra Region Cancer Centre, The Canberra Hospital, Canberra, ACT, Australia.
John ZalcbergAlfred Health, Monash University, Melbourne, VIC, Australia.
Timothy J PriceThe Queen Elizabeth Hospital/University of Adelaide, Adelaide, SA, Australia.ORCID http://orcid.org/0000-0002-3922-2693
Adnan NagrialDepartment of Medical Oncology, Westmead and Blacktown Hospitals, University of Sydney, Sydney, NSW, Australia.
Lorraine ChantrillDepartment of Medical Oncology, Wollongong Hospital, Illawarra Shoalhaven Local Health District, Illawarra, NSW, Australia.
Matt BurgeDepartment of Cancer Care Services, Royal Brisbane Hospital, University of Queensland, Herston, QLD, Australia.
Christos S KarapetisFlinders Centre for Innovation in Cancer/Flinders University, Bedford Park, SA, 5042, Australia.
Niall TebbuttDepartment of Medical Oncology, Olivia Newton-John Cancer Wellness and Research Centre, Austin Health, Heidelberg, VIC, Australia.
Amitesh C RoyFlinders Centre for Innovation in Cancer/Flinders University, Bedford Park, SA, 5042, Australia. amitesh.roy@sa.gov.au.
Flinders University · AUThe University of Sydney · AUAlfred Health · AUCabrini Hospital · AUCanberra Hospital · AUMonash Health · AUOlivia Newton-John Cancer Wellness & Research Centre · AUPeter MacCallum Cancer Centre · AUPrince of Wales Hospital · AUQueen Elizabeth Hospital · AUThe University of Queensland · AUWollongong Hospital · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastrointestinal stromal tumours (GISTs) are the most common gastrointestinal tract mesenchymal tumours. Tyrosine kinase inhibitors (TKIs) have transformed the management of advanced GIST. Imatinib was the first TKI to gain approval as management for patients with advanced GIST, establishing a new standard of care. Since then, as a result of several trials including the GRID and INVICTUS studies, we now have five lines of approved targeted therapy, including imatinib, sunitinib, regorafenib, ripretinib and avapritinib for the treatment of unresectable, advanced GISTs. In this review, the Australasian Gastrointestinal Trials Group (AGITG) provide an overview of the key trials that have changed clinical practice, discuss the molecular drivers of GISTs, the importance of molecular testing and directing therapy according to molecular targets, as well as future strategies in the management of advanced GISTs.

Indexed as

Antineoplastic AgentsGastrointestinal NeoplasmsGastrointestinal Stromal TumorsHumansImatinib MesylateProtein Kinase InhibitorsSunitinibAntineoplastic AgentsImatinib MesylateProtein Kinase InhibitorsSunitinib

Identifiers

PMID35290591
PMCPMC8995292
OpenAlexW4221074758

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.